J Pediatr Intensive Care 2020; 09(02): 106-112
DOI: 10.1055/s-0039-1700953
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Single-Center Use of Prothrombin Complex Concentrate in Pediatric Patients

1   Division of Pediatric Critical Care Medicine, Nationwide Children's Hospital, Columbus, Ohio, United States
Courtney Andersen
2   Ohio University Heritage College of Osteopathic Medicine, Dublin, Ohio, United States
3   Division of Pediatric Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, United States
4   Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, United States
5   Department of Anesthesiology and Pain Medicine, The Ohio State University College of Medicine, Columbus, Ohio, United States
› Institutsangaben
Weitere Informationen


13. Oktober 2019

06. Dezember 2019

10. Januar 2020 (online)


Coagulation disturbances frequently occur in critically ill children. Four-factor prothrombin complex concentrate (4F-PCC) may have a potential role in managing these patients while avoiding concerns associated with fresh frozen plasma. However, data on this product in critically ill children is scarce. We retrospectively identified 24 critically ill pediatric patients who received 4F-PCC. The primary indication was to correct coagulopathy and control bleeding in the trauma or surgical setting. 4F-PCC effectively decreased the international normalized ratio level, a surrogate marker of hemostasis. Further study is warranted to identify efficacy, indications, optimal dosing, and adverse effects in the critically ill pediatric patients.

  • References

  • 1 Ghadimi K, Levy JH, Welsby IJ. Perioperative management of the bleeding patient. Br J Anaesth 2016; 117 (Suppl. 03) iii18-iii30
  • 2 Parker RI. Coagulopathies in the PICU: DIC and liver disease. Crit Care Clin 2013; 29 (02) 319-333
  • 3 Goobie SM, DiNardo JA, Faraoni D. Relationship between transfusion volume and outcomes in children undergoing noncardiac surgery. Transfusion 2016; 56 (10) 2487-2494
  • 4 Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology (Am Soc Hematol Educ Program) 2007; 179-186 . Available at: https://pdfs.semanticscholar.org/4a9a/0b91c650e4bafc72b1ff909b7c853162f3e6.pdf?_ga=2.137057776.1155333959.1584517369-572925867.1564467732 . Accessed March 18, 2020
  • 5 Karam O, Lacroix J, Robitaille N, Rimensberger PC, Tucci M. Association between plasma transfusions and clinical outcome in critically ill children: a prospective observational study. Vox Sang 2013; 104 (04) 342-349
  • 6 Watson GA, Sperry JL, Rosengart MR. , et al; Inflammation and Host Response to Injury Investigators. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma 2009; 67 (02) 221-227 , discussion 228–230
  • 7 Marshall AL, Levine M, Howell ML. , et al. Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. J Thromb Haemost 2016; 14 (02) 324-330
  • 8 Figueiredo S, Benhamou D. Use of fresh frozen plasma: from the 2012 French guidelines to recent advances. Transfus Apheresis Sci 2017; 56 (01) 20-25
  • 9 Galanaud JP, Pelletier-Fleury N, Logerot-Lebrun H, Lambert T. Determinants of drug costs in hospitalised patients with haemophilia: impact of recombinant activated factor VII. Pharmacoeconomics 2003; 21 (10) 699-707
  • 10 Stein DM, Dutton RP, Hess JR, Scalea TM. Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 2008; 39 (09) 1054-1061
  • 11 Hollis AL, Lowery AV, Pajoumand M. , et al. Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation. Ann Card Anaesth 2016; 19 (03) 418-424
  • 12 Sarode R, Milling Jr TJ, Refaai MA. , et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128 (11) 1234-1243
  • 13 Ortmann E, Besser MW, Sharples LD. , et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 2015; 121 (01) 26-33
  • 14 Zeeshan M, Hamidi M, Feinstein AJ. , et al. Four-factor prothrombin complex concentrate is associated with improved survival in trauma-related hemorrhage: a nationwide propensity-matched analysis. J Trauma Acute Care Surg 2019; 87 (02) 274-281
  • 15 Joseph B, Aziz H, Pandit V. , et al. Prothrombin complex concentrate versus fresh-frozen plasma for reversal of coagulopathy of trauma: is there a difference?. World J Surg 2014; 38 (08) 1875-1881
  • 16 Arnékian V, Camous J, Fattal S, Rézaiguia-Delclaux S, Nottin R, Stéphan F. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg 2012; 15 (03) 382-389
  • 17 Enter DH, Zaki AL, Marsh M. , et al. Prothrombin complex concentrate reduces blood product utilization in heart transplantation. Pharmacotherapy 2017; 37 (10) 1215-1220
  • 18 Edavettal M, Rogers A, Rogers F, Horst M, Leng W. Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients. Am Surg 2014; 80 (04) 372-376
  • 19 Jehan F, Aziz H, O'Keeffe T. , et al. The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: a propensity matched analysis. J Trauma Acute Care Surg 2018; 85 (01) 18-24
  • 20 Ashikhmina E, Said S, Smith MM. , et al. Prothrombin complex concentrates in pediatric cardiac surgery: the current state and the future. Ann Thorac Surg 2017; 104 (04) 1423-1431
  • 21 Rech MA, Wittekindt L, Friedman SD, Kling K, Ubogy D. Prothrombin complex concentrate for intracerebral hemorrhage secondary to vitamin K deficiency bleeding in a 6-week-old child. J Pediatr 2015; 167 (06) 1443-1444
  • 22 Noga T, Bruce AA, Blain H, Nahirniak S. Four-factor prothrombin complex concentrates in paediatric patients - a retrospective case series. Vox Sang 2016; 110 (03) 253-257
  • 23 Guzzetta NA, Williams GD. Current use of factor concentrates in pediatric cardiac anesthesia. Paediatr Anaesth 2017; 27 (07) 678-687
  • 24 Webster DL, Fei L, Falcone RA, Kaplan JM. Higher-volume hypertonic saline and increased thrombotic risk in pediatric traumatic brain injury. J Crit Care 2015; 30 (06) 1267-1271
  • 25 Hanson SJ, Punzalan RC, Greenup RA, Liu H, Sato TT, Havens PL. Incidence and risk factors for venous thromboembolism in critically ill children after trauma. J Trauma 2010; 68 (01) 52-56
  • 26 Leeper CM, Vissa M, Cooper JD, Malec LM, Gaines BA. Venous thromboembolism in pediatric trauma patients: ten-year experience and long-term follow-up in a tertiary care center. Pediatr Blood Canc 2017 64. (08). doi: 10.1002/pbc.26415
  • 27 Easley RB. Venous thromboembolism in the pediatric intensive care unit: increased incidence or increased awareness?. Pediatr Crit Care Med 2011; 12 (06) 678-680
  • 28 Higgerson RA, Lawson KA, Christie LM. , et al; National Association of Children's Hospitals and Related Institution's Pediatric Intensive Care Unit FOCUS group. Incidence and risk factors associated with venous thrombotic events in pediatric intensive care unit patients. Pediatr Crit Care Med 2011; 12 (06) 628-634